Ensituximab is under clinical development by Precision Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ensituximab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ensituximab overview
Ensituximab (NPC-1C, NEO-101, NEO-102) is under development for the treatment of solid tumor and metastatic colorectal cancer. It is administered as an infusion through intravenous route. The drug candidate is a chimeric monoclonal antibody that acts by targeting cells expressing mucin 5ac (MUC5AC). It is developed based on Selexis SURE technology.
It was under development for the treatment of refractory metastatic pancreatic cancer.
Precision Biologics overview
Precision Biologics (PBI), a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company. The company’s product portfolio includes NEO-201, NEO-201 + Pembrolizumab and NEO-201 + IL – 15. Its lead drug candidate NEO-201, is used to treat patients with advanced metastatic colorectal cancer based on minimal side effects observed in patients using Ensituximab. The company’s NEO – 201 + Pembrolizumab treats second-line metastatic head and neck cancers, endometrial cancer, cervical cancer, NEO – 201 + IL – 15, treats colorectal cancer and NEO – 201, treats blood tumors and other malignancies (TBD). PBI is headquartered in Rockville, Maryland, the US.
For a complete picture of Ensituximab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
